{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-028601","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.038284+00:00","generated_at":"2026-05-15T00:33:54.942388+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Alnylam Q1 net product revs $1.04B (+121%); GAAP EPS $1.51 vs -$0.14; reaffirms FY26 guidance","bullets":["Global net product revenues $1,036M, up 121% YoY; total TTR revenues $910M (+153%).","GAAP net income $206M vs loss $18M; GAAP diluted EPS $1.51; non-GAAP EPS $1.99.","Reiterates FY26 combined net product revenue guidance of $4.9B-$5.3B.","AMVUTTRA (vutrisiran) net product revenues $890M; TRITON-CM expanded to ~1,750 patients.","Initiated Phase 1 obesity trial (ALN-2232) and new collaborations with Viz.ai, AHA, Tenaya, Helix."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-028601","json":"https://secwatch.observer/filing/0001628280-26-028601.json","markdown":"https://secwatch.observer/filing/0001628280-26-028601.md","text":"https://secwatch.observer/filing/0001628280-26-028601.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000162828026028601/0001628280-26-028601-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000162828026028601/alny-20260430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:33:54.942388+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1e02ac1cddef3f313eaea33893cc596c07fe4e97","claim":"ALNYLAM PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2026 results: revenue $1,036 Million. Guidance reaffirmed.","evidence_excerpt":"Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress − Achieved First Quarter 2026 Global Net Product Revenues of $1,036 Million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000162828026028601/0001628280-26-028601-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"$1,036 Million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}